• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 144-158 of 455 results

1001 Exhibit: 1001 USPN 6,858,650

Document IPR2016-01665, No. 1001 Exhibit - 1001 USPN 6,858,650 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1029 Exhibit: 1029 Takeuchi 1997

Document IPR2016-01665, No. 1029-29 Exhibit - 1029 Takeuchi 1997 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1033 Exhibit: 1033 Declaration of DeForest McDuff, PhD

Document IPR2016-01665, No. 1033-33 Exhibit - 1033 Declaration of DeForest McDuff, PhD (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1039 Exhibit: 1039 US OAB Market Share Prescriptions and Sales by Drug 2000 20...

Document IPR2016-01665, No. 1039-39 Exhibit - 1039 US OAB Market Share Prescriptions and Sales by Drug 2000 2007 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1015 Exhibit: 1015 Nilvebrant Pharmacology and Toxicology 1997

Document IPR2016-01665, No. 1015-15 Exhibit - 1015 Nilvebrant Pharmacology and Toxicology 1997 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1040 Exhibit: 1040 Prescription Path of Toviaz and Other OABs

Document IPR2016-01665, No. 1040-40 Exhibit - 1040 Prescription Path of Toviaz and Other OABs (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1026 Exhibit: 1026 FDA Guidance October 1999

Document IPR2016-01665, No. 1026-26 Exhibit - 1026 FDA Guidance October 1999 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1023 Exhibit: 1023 PM360 April 1, 2012 Overactive Bladder Market

Document IPR2016-01665, No. 1023-23 Exhibit - 1023 PM360 April 1, 2012 Overactive Bladder Market (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1045 Exhibit: 1045 Present Value of Toviaz US Sales

Document IPR2016-01665, No. 1045-45 Exhibit - 1045 Present Value of Toviaz US Sales (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1032 Exhibit: 1032 Dkt 6 2015 01 28 Summons 15 cv 00079, Pfizer,et al v Mylan Ph...

Document IPR2016-01665, No. 1032-32 Exhibit - 1032 Dkt 6 2015 01 28 Summons 15 cv 00079, Pfizer,et al v Mylan Pharm (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1053 Exhibit: 1012 Bundgaard Design of Prodrugs 1985 Part 2

Document IPR2016-01665, No. 1053-53 Exhibit - 1012 Bundgaard Design of Prodrugs 1985 Part 2 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1035 Exhibit: 1035 Toviaz Dont Let Overactive Bladder Stop You In Your Tracks

Document IPR2016-01665, No. 1035-35 Exhibit - 1035 Toviaz Dont Let Overactive Bladder Stop You In Your Tracks (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1028 Exhibit: 1028 Alabaster 1997

Document IPR2016-01665, No. 1028-28 Exhibit - 1028 Alabaster 1997 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1020 Exhibit: 1020 Bundgaard WO 9208459

Document IPR2016-01665, No. 1020-20 Exhibit - 1020 Bundgaard WO 9208459 (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze

1043 Exhibit: 1043 Comparison of Toviaz Sales to Compound to Pharmaceutical In...

Document IPR2016-01665, No. 1043-43 Exhibit - 1043 Comparison of Toviaz Sales to Compound to Pharmaceutical Industry (P.T.A.B. Aug. 22, 2016)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 10 11 12 13 14 ... >>